OTCMKTS:TLOG TetraLogic Pharmaceuticals (TLOG) Stock Price, News & Analysis $0.0002 0.00 (0.00%) As of 09/12/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsShort InterestBuy This Stock About TetraLogic Pharmaceuticals Stock (OTCMKTS:TLOG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TLOG alerts:Sign Up Key Stats Today's Range$0.0002▼$0.000250-Day Range N/A52-Week Range$0.0001▼$0.0010VolumeN/AAverage Volume45 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview TetraLogic Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel immunotherapies and small-molecule therapeutics for the treatment of cancer and infectious diseases. Its primary focus is on synthetic carbohydrate-based vaccines that stimulate targeted immune responses against tumor-associated antigens, complemented by a small-molecule antibiotic platform designed to combat drug-resistant bacterial pathogens. The company’s lead immunotherapy candidate, which targets mucin-based tumor antigens, is under evaluation in early-phase clinical trials in collaboration with academic research centers, with particular emphasis on breast and ovarian cancer indications. In parallel, TetraLogic advances a pipeline of preclinical small-molecule compounds engineered to disrupt essential bacterial survival mechanisms, addressing growing antibiotic resistance. Headquartered in Bothell, Washington, TetraLogic was founded in the mid-2000s and leverages partnerships with research institutions to support discovery and development. The management team draws on extensive experience in oncology drug development and infectious disease research to guide the company’s strategic growth.AI Generated. May Contain Errors. Read More Receive TLOG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TetraLogic Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TLOG Stock News HeadlinesTLOG TetraLogic Pharmaceuticals Corporation - Seeking AlphaJune 27, 2025 | seekingalpha.comTetraLogic Pharmaceuticals Corp (TLOG)May 5, 2025 | nasdaq.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd. | Brownstone Research (Ad)TetraLogic Pharmaceuticals Corporation (TLOG)August 29, 2024 | sg.finance.yahoo.comInovio Pharmaceuticals, Inc. Common Stock (INO)January 28, 2024 | nasdaq.comTetraLogic Pharma (TLOG) Earnings Dates & ReportsAugust 4, 2023 | investing.comSee More Headlines TLOG Stock Analysis - Frequently Asked Questions How have TLOG shares performed this year? TetraLogic Pharmaceuticals' stock was trading at $0.0001 on January 1st, 2025. Since then, TLOG stock has increased by 100.0% and is now trading at $0.0002. How do I buy shares of TetraLogic Pharmaceuticals? Shares of TLOG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TetraLogic Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that TetraLogic Pharmaceuticals investors own include Bristol Myers Squibb (BMY), Trevena (TRVN), Vaxart (VXRT), Arrowhead Pharmaceuticals (ARWR), Sangamo Therapeutics (SGMO), Achieve Life Sciences (ACHV) and Gilead Sciences (GILD). Company Calendar Today9/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:TLOG Previous SymbolNASDAQ:TLOG CIK1361248 Webwww.tetralogicpharma.com Phone(610) 889-9900Fax610-889-9994Employees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta5.10 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (OTCMKTS:TLOG) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...Porter & Company | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TetraLogic Pharmaceuticals Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share TetraLogic Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.